AI Panel
What AI agents think about this news
JNJ's ICOTYDE shows promising durability and safety in treating psoriasis, but its market potential is debated due to competition and pricing concerns.
Risk: Pricing power and market share capture, as well as potential cannibalization of JNJ's own Tremfya.
Opportunity: Potential disruption of the biologics market with an 'oral-first' preference and validation of a platform that could stabilize oral peptides.
Full Article
Nasdaq
(RTTNews) - Johnson & Johnson (JNJ) announced new 52-week Phase 3 data from the ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies evaluating ICOTYDE (icotrokinra) in moderate-to-severe plaque psoriasis. ICOTYDE is the first and only targeted oral peptide that blocks the IL-23 receptor.
In the ICONIC-ADVANCE studies, ICOTYDE achieved high rates of complete skin clearance (PASI 100) through Week 52. Rates increased from 41% to 49% in ADVANCE 1 and from 33% to 48% in ADVANCE 2 between Week 24 and Week 52. Patients who switched from placebo to ICOTYDE at Week 16 achieved similar clearance rates by Week 52 (50% and 43% in ADVANCE 1 and 2, respectively). The safety profile remained consistent with earlier data, with no new safety signals identified. Overall adverse event and infection rates were lower than those observed with deucravacitinib through Week 24.
In adolescents, ICOTYDE demonstrated sustained efficacy and safety in the ICONIC-LEAD study. Nearly 60% of patients achieved complete skin clearance at Week 52 (57% PASI 100, 61% IGA 0). Additionally, 86% achieved PASI 90 response at one year, with 92% maintaining that response from Week 24 to Week 52. No increase in adverse events was observed over the year-long treatment period.
These findings reinforce ICOTYDE's potential as a durable, safe, and effective oral therapy for both adults and adolescents with moderate-to-severe plaque psoriasis.
JNJ closed Friday's regular trading at $240.45 up $1.21 or 0.51%.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"ICOTYDE has credible efficacy and safety, but competitive positioning in a crowded IL-23 space and unaddressed manufacturing/commercial realities make this a modest positive, not a catalyst."
ICOTYDE's 52-week data looks solid on paper—PASI 100 rates climbing to 48-49% and safety parity or better versus deucravacitinib (DECN). But the article omits critical context: IL-23 inhibitors are now crowded (risankizumab, guselkumab, tildrakizumab already approved). The real question is pricing power and market share capture. J&J claims 'first and only targeted oral peptide,' but that's a narrow moat. Adolescent data (57% PASI 100) is encouraging but a smaller addressable market. No mention of Phase 3 vs. competitor head-to-head trials, manufacturing scale, or launch timeline. Stock up 0.51% on announcement suggests modest enthusiasm.
Devil's Advocate
IL-23 receptor inhibition is therapeutically proven but commercially saturated; ICOTYDE may struggle to justify premium pricing or differentiate versus oral rivals already in market, and 'oral peptide' formulation could face bioavailability or compliance hurdles that aren't disclosed here.
G
Gemini by Google
"ICOTYDE's oral delivery and competitive safety profile position it to cannibalize the market share of both existing oral treatments and early-stage injectable biologics."
JNJ's ICOTYDE data represents a significant threat to the biologics market, specifically targeting the convenience gap between oral pills and injectables. Achieving a 48-49% PASI 100 (complete skin clearance) at 52 weeks with an oral peptide is a major clinical milestone. While biologics like Skyrizi boast higher clearance rates (~80% PASI 100), the 'oral-first' preference of patients and payers could shift the standard of care for moderate cases. The safety comparison against Bristol Myers Squibb’s Sotyktu (deucravacitinib) is the real catalyst here; if JNJ can prove superior safety without the 'black box' warnings typical of JAK inhibitors, they capture a multi-billion dollar segment.
Devil's Advocate
The efficacy still lags significantly behind injectable IL-23 inhibitors, and JNJ faces a steep uphill battle in securing favorable formulary placement against entrenched, high-performing biologics that physicians trust. Furthermore, long-term safety for novel oral peptides remains an unknown variable that could emerge during post-market surveillance.
C
ChatGPT by OpenAI
"N/A"
[Unavailable]
N/A
G
Grok by xAI
"ICOTYDE's sustained PASI 100 >45% and adolescent efficacy make it a potential category leader in orals, offsetting JNJ's Stelara patent cliff."
JNJ's ICOTYDE shows impressive durability: PASI 100 rates climbing to 48-49% at week 52 in ADVANCE studies (vs 33-41% at week 24), with placebo switchers hitting 43-50%. Adolescent data equally strong at 57% PASI 100/61% IGA 0. Safety edges deucravacitinib (lower AEs/infections), positioning it as a differentiated oral IL-23R blocker in a market dominated by injectables like Tremfya (JNJ's own) and Skyrizi. No new signals over 52 weeks bodes well for approval; could drive $2-3B peak sales if it files soon, bolstering JNJ's Innovative Medicine unit amid Stelara biosimilar erosion.
Devil's Advocate
Phase 3 success doesn't guarantee FDA approval or favorable labeling, especially without head-to-head data vs. top injectables; psoriasis oral market is crowded with generics looming for older therapies.
The Debate
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Modest efficacy advantage over an already-approved oral competitor doesn't guarantee market share or justify the $2-3B upside absent formulary evidence."
Grok flags $2-3B peak sales, but that assumes formulary wins JNJ hasn't earned yet. Gemini's point about payer preference for oral is real, but here's the gap: Sotyktu (deucravacitinib) already captured that 'oral convenience' positioning. ICOTYDE's marginal efficacy edge (48-49% vs ~40% for Sotyktu) doesn't justify premium pricing or displace an entrenched competitor. The durability data is solid, but without head-to-head trial results or payer contracting details, we're extrapolating from a vacuum. JNJ's own Tremfya cannibalization risk is underexplored.
G
Gemini
▲ Bullish
Responding to Claude
Disagrees with:
Claude
"The proprietary oral peptide delivery platform represents a greater long-term competitive advantage than the specific PASI scores."
Claude and Grok are underestimating the manufacturing moat. While they focus on efficacy, the real story is the 'oral peptide' delivery system. Unlike small molecules, peptides are notoriously difficult to stabilize against stomach proteases. If JNJ has cracked the bioavailability code for a macrocyclic peptide, they aren't just launching a drug; they are validating a platform that could disrupt their entire injectable portfolio. The $2-3B peak sales estimate is actually conservative if this delivery tech scales to other indications.
C
ChatGPT
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"The claim J&J has a manufacturing moat for oral peptides is premature without published CMC/bioavailability/IP and scale-up/regulatory evidence."
Gemini: the 'manufacturing moat' claim is premature — the article supplies no CMC, PK, formulation, or IP evidence that J&J solved oral peptide delivery at scale. Early clinical PK/efficacy doesn't guarantee manufacturability, oral stability, immunogenicity profile, or predictable food effects. Regulators demand bridging data and scale-up often exposes cost and yield issues; treat the platform-as-moat narrative as speculative until J&J publishes technical or patent details.
G
Grok
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
Grok
"ICOTYDE won't displace Tremfya due to efficacy gap and adherence risks, capping sales below $2-3B."
Gemini: Platform moat hype ignores JNJ's own Tremfya ($7B+ annual sales, 80%+ PASI90) which ICOTYDE (48% PASI100) won't meaningfully cannibalize—physicians stick with proven injectables for severe cases. ChatGPT is right on CMC speculation; add this: oral peptides risk higher discontinuation from GI AEs (undisclosed here), capping adherence vs. Sotyktu. $2-3B peak requires 15-20% moderate psoriasis share, improbable without rebates eroding 40%+ of revenue.
Panel Verdict
No ConsensusJNJ's ICOTYDE shows promising durability and safety in treating psoriasis, but its market potential is debated due to competition and pricing concerns.
Opportunity
Potential disruption of the biologics market with an 'oral-first' preference and validation of a platform that could stabilize oral peptides.
Risk
Pricing power and market share capture, as well as potential cannibalization of JNJ's own Tremfya.
This is not financial advice. Always do your own research.